Effects of Clostridium difficile toxins given intragastrically to animals.

PubWeight™: 5.44‹?› | Rank: Top 1%

🔗 View Article (PMC 263173)

Published in Infect Immun on February 01, 1985

Authors

D M Lyerly, K E Saum, D K MacDonald, T D Wilkins

Articles citing this

(truncated to the top 100)

Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol (2009) 7.89

Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26

Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69

Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49

The role of toxin A and toxin B in Clostridium difficile infection. Nature (2010) 5.32

Clostridial enteric diseases of domestic animals. Clin Microbiol Rev (1996) 4.97

A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol (1998) 4.79

Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev (1996) 3.46

Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol (1998) 3.34

Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91

Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89

Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol (2007) 2.77

Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol (2000) 2.50

CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci U S A (1994) 2.22

Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev (1993) 2.19

Dentists, antibiotics and Clostridium difficile-associated disease. Br Dent J (2015) 2.10

Multicenter evaluation of the Clostridium difficile TOX A/B TEST. J Clin Microbiol (1998) 2.09

Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.07

Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun (1987) 2.06

Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01

Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00

Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol (2008) 1.89

Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun (2001) 1.88

Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut (1996) 1.79

Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol (2004) 1.73

Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66

Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun (2000) 1.60

Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57

Antisecretory factor suppresses intestinal inflammation and hypersecretion. Gut (1997) 1.57

Nucleotide sequence of Clostridium difficile toxin A. Nucleic Acids Res (1990) 1.55

The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. J Clin Invest (1995) 1.51

Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun (1991) 1.44

Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42

Spironolactone and colitis: increased mortality in rodents and in humans. Inflamm Bowel Dis (2011) 1.40

Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun (1988) 1.40

Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. J Clin Invest (1997) 1.39

Structure-function analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difficile toxin A. J Biol Chem (2009) 1.39

Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis (2010) 1.38

The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes (2010) 1.37

Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36

Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc Natl Acad Sci U S A (2006) 1.35

Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun (1995) 1.35

gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect Immun (2008) 1.30

Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes (2011) 1.29

Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest (1992) 1.28

Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR. J Clin Microbiol (2000) 1.28

Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun (1999) 1.25

Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25

Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun (2011) 1.24

International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants. J Clin Microbiol (2003) 1.23

A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22

Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol (2012) 1.22

Clostridium difficile toxins: mediators of inflammation. J Innate Immun (2012) 1.21

Antigenic cross-reactivity and functional inhibition by antibodies to Clostridium difficile toxin A, Streptococcus mutans glucan-binding protein, and a synthetic peptide. Infect Immun (1991) 1.21

Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun (1999) 1.20

Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16

Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A. Can J Infect Dis (2004) 1.16

Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine. Gut (1990) 1.15

Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci (2010) 1.13

Comparison of two commercially available enzyme immunoassays for detection of Clostridium difficile in stool specimens. J Clin Microbiol (1994) 1.12

Effect of various diets on toxin production by two strains of Clostridium difficile in gnotobiotic mice. Infect Immun (1987) 1.11

Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis. Infect Immun (1998) 1.10

Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun (1999) 1.09

Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. Infect Immun (1997) 1.07

Interrelationships between digestive proteolytic activities and production and quantitation of toxins in pseudomembranous colitis induced by Clostridium difficile in gnotobiotic mice. Infect Immun (1989) 1.07

The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07

Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes (2011) 1.06

Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect Immun (1995) 1.05

Comparison of the premier toxin A and B assay and the TOX A/B II assay for diagnosis of Clostridium difficile infection. Clin Vaccine Immunol (2008) 1.03

A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin Vaccine Immunol (2013) 1.03

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology (2013) 1.02

Structural basis for substrate recognition in the enzymatic component of ADP-ribosyltransferase toxin CDTa from Clostridium difficile. J Biol Chem (2009) 1.00

Clostridium difficile infection. Nat Rev Dis Prim (2016) 0.99

Variations in virulence and molecular biology among emerging strains of Clostridium difficile. Microbiol Mol Biol Rev (2013) 0.99

Structural determinants of Clostridium difficile toxin A glucosyltransferase activity. J Biol Chem (2012) 0.99

Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-alpha by macrophages. Microb Pathog (2009) 0.99

Novel one-step method for detection and isolation of active-toxin-producing Clostridium difficile strains directly from stool samples. J Clin Microbiol (2011) 0.98

In vivo physiological and transcriptional profiling reveals host responses to Clostridium difficile toxin A and toxin B. Infect Immun (2013) 0.98

Binding kinetics of Clostridium difficile toxins A and B to intestinal brush border membranes from infant and adult hamsters. Infect Immun (1991) 0.97

Construction and expression of the complete Clostridium difficile toxin A gene in Escherichia coli. Infect Immun (1991) 0.96

Immune responses to Clostridium difficile infection. Trends Mol Med (2012) 0.95

Clostridium difficile toxin A-induced microvascular dysfunction. Role of histamine. J Clin Invest (1994) 0.94

Purification and characterization of toxin B from Clostridium difficile. Infect Immun (1988) 0.94

A segment of 97 amino acids within the translocation domain of Clostridium difficile toxin B is essential for toxicity. PLoS One (2013) 0.93

Isolation of Clostridium difficile and detection of cytotoxin in the feces of diarrheic foals in the absence of antimicrobial treatment. J Clin Microbiol (1987) 0.92

The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia. Nat Microbiol (2016) 0.92

CodY-Dependent Regulation of Sporulation in Clostridium difficile. J Bacteriol (2016) 0.92

Toxin synthesis by Clostridium difficile is regulated through quorum signaling. MBio (2015) 0.91

Relationship between levels of Clostridium difficile toxin A and toxin B and cecal lesions in gnotobiotic mice. Infect Immun (1989) 0.91

Effect of Clostridium difficile enterotoxin A on ultrastructure of Chinese hamster ovary cells. Infect Immun (1989) 0.91

Immunoblot analysis of serum immunoglobulin G response to surface proteins of Clostridium difficile in patients with antibiotic-associated diarrhea. J Clin Microbiol (1989) 0.90

Purification and characterization of alpha-toxin produced by Clostridium novyi type A. Infect Immun (1993) 0.89

Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. Infect Immun (2012) 0.89

Factors influencing the phagocytosis of Clostridium difficile by human polymorphonuclear leukocytes. Infect Immun (1987) 0.88

Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives. Toxins (Basel) (2010) 0.88

The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B. Immunology (1997) 0.87

Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol (2014) 0.87

Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen. Gut Microbes (2014) 0.86

Antiapoptotic proteins Bcl-2 and Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells. Infect Immun (2009) 0.85

Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant. Infect Immun (2004) 0.85

Articles cited by this

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81

Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88

A new method for the large-scale production of high-titre botulinum formol-toxoid types C and D. J Immunol (1950) 5.19

Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16

Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62

The effect of Clostridium welchii type D culture filtrates on the permeability of the mouse intestine. J Pathol Bacteriol (1956) 4.10

Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95

Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93

Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40

Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65

Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology (1980) 2.60

Clostridial toxin in faeces of healthy infants. Lancet (1978) 2.58

Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet (1980) 2.24

Clostridium difficile in gnotobiotic mice. Infect Immun (1980) 2.17

Clostridium difficile toxin in asymptomatic neonates. J Pediatr (1982) 1.88

Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms. Infect Immun (1982) 1.87

Clostridium difficile toxin A in infants. J Infect Dis (1983) 1.53

Morphology of experimental antibiotic-associated enterocolitis in the hamster: a model for human pseudomembranous colitis and antibiotic-associated diarrhoea. Gut (1979) 1.53

Pseudomembranous colitis in Clostridium difficile-monoassociated rats. Infect Immun (1983) 1.51

Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology (1982) 1.43

Toxin A of Clostridium difficile: production, purification and effect in mouse intestine. Acta Pathol Microbiol Immunol Scand B (1983) 1.37

Arousal of mucosal secretory immunoglobulin A antitoxin in rats immunized with Escherichia coli heat-labile enterotoxin. Infect Immun (1982) 1.36

Protection in rabbits immunized with a vaccine of Escherichia coli heat-stable toxin cross-linked to the heat-labile toxin B subunit. Infect Immun (1983) 1.19

Clostridium difficile colitis unassociated with antibiotic therapy. Br J Surg (1983) 1.15

Toxin-producing bacteria in infants. Lack of an association with sudden infant death syndrome. Am J Dis Child (1981) 1.06

Implication of Clostridium difficile and Clostridium perfringens iota toxins in experimental lincomycin-associated colitis of rabbits. Lab Anim Sci (1982) 1.03

Relapse of Clostridium colitis after vancomycin therapy. J Antimicrob Chemother (1980) 0.98

Peroral immunization of rats with Escherichia coli heat-labile enterotoxin delivered by microspheres. Infect Immun (1983) 0.97

Clostridium difficile typhlitis in hamsters not associated with antibiotic therapy--. J Am Vet Med Assoc (1982) 0.95

Articles by these authors

Medium for use in antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1976) 9.38

Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria. Antimicrob Agents Chemother (1973) 9.35

Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol (1977) 8.29

Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26

Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88

Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1979) 5.10

Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62

Development of a micromethod for identification of anaerobic bacteria. Appl Microbiol (1975) 4.58

Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl Environ Microbiol (1977) 4.09

Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06

Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95

Micromethod for identification of anaerobic bacteria: design and operation of apparatus. Appl Microbiol (1975) 3.80

Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40

Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93

Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89

Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol (1982) 2.86

Arginine, a growth-limiting factor for Eubacterium lentum. J Bacteriol (1976) 2.67

Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65

Production by Salmonella typhimurium of 2,3-dihydroxybenzoylserine, and its stimulation of growth in human serum. J Infect Dis (1970) 2.62

Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49

Medium-dependent inhibition of Peptostreptococcus anaerobius by sodium polyanetholsulfonate in blood culture media. J Clin Microbiol (1976) 2.46

Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46

Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14

The enterotoxin of Bacteroides fragilis is a metalloprotease. Infect Immun (1995) 2.06

Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01

Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00

Purification and characterization of an enterotoxin from Bacteroides fragilis. Infect Immun (1992) 1.97

Entamoeba histolytica and Entamoeba dispar infection in children in Bangladesh. J Infect Dis (1997) 1.95

Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol (1986) 1.92

Differential effects of Clostridium difficile toxins on tissue-cultured cells. J Clin Microbiol (1982) 1.87

Resistance of some species of Clostridium to clindamycin. Antimicrob Agents Chemother (1973) 1.81

Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics. Antimicrob Agents Chemother (1978) 1.78

In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis. Antimicrob Agents Chemother (1975) 1.78

Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol (1982) 1.75

Chemotherapy of an experimental Fusobacterium (Sphaerophorus) necrophorum infection in mice. Antimicrob Agents Chemother (1974) 1.71

Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol (2004) 1.71

Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol (1991) 1.67

Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66

Deletions in the repeating sequences of the toxin A gene of toxin A-negative, toxin B-positive Clostridium difficile strains. FEMS Microbiol Lett (1999) 1.66

Fibrinolytic activity of oral anaerobic bacteria. Arch Oral Biol (1978) 1.65

Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65

Use of semisolid agar from initiation of pure Bacteroides fragilis infection in mice. Infect Immun (1976) 1.64

Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology (1996) 1.63

Inhibition of Bacteroides fragilis on blood agar plates and reversal of inhibition by added hemin. J Clin Microbiol (1976) 1.63

Beta-Lactamase activity in strains of Bacteroides melaninogenicus and Bacteroides oralis. Antimicrob Agents Chemother (1977) 1.62

Laminarinase (beta-glucanase) activity in Bacteroides from the human colon. Appl Environ Microbiol (1977) 1.61

Proteolytic activity of the Bacteroides fragilis enterotoxin causes fluid secretion and intestinal damage in vivo. Infect Immun (1995) 1.59

Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57

Purification and characterization of Clostridium perfringens iota toxin: dependence on two nonlinked proteins for biological activity. Infect Immun (1986) 1.57

Requirement of heme for growth of Bacteroides fragilis. Appl Environ Microbiol (1977) 1.53

Clostridium difficile toxin A in infants. J Infect Dis (1983) 1.53

Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal alpha 1-3Gal beta 1-4GlcNAc sequences. Arch Biochem Biophys (1987) 1.51

Vaspar broth-disk procedure for antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1980) 1.50

Molecular basis for the pathological actions of Clostridium perfringens iota toxin. Infect Immun (1987) 1.47

Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile. J Med Microbiol (1992) 1.47

The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells. Infect Immun (1997) 1.46

Cytochrome spectrum of an obligate anaerobe, Eubacterium lentum. J Bacteriol (1976) 1.45

Bacteriophages of Bacteroides. Rev Infect Dis (1980) 1.44

Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun (1991) 1.44

Clostridium perfringens iota toxin: synergism between two proteins. Toxicon (1986) 1.43

Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42

Cholesterol-reducing bacterium from human feces. Appl Environ Microbiol (1977) 1.40

Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun (1988) 1.40

Influence of pencillinase production by strains of Bacteroides melaninogenicus and Bacteriodes oralis on pencillin therapy of an experimental mixed anaerobic infection in mice. Arch Oral Biol (1976) 1.39

Cloning and characterization of the gene for the metalloprotease enterotoxin of Bacteroides fragilis. FEMS Microbiol Lett (1997) 1.36

Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun (1995) 1.35

Characterization of cross-reactive proteins detected by Culturette Brand Rapid Latex Test for Clostridium difficile. J Clin Microbiol (1988) 1.34

Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. Diagn Microbiol Infect Dis (1986) 1.34

Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun (1992) 1.32

Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR. J Clin Microbiol (2000) 1.28

Susceptibility of anaerobic bacteria to sulfamethoxazole/trimethoprim and routine susceptibility testing. Antimicrob Agents Chemother (1978) 1.26

Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest (1996) 1.26

Importance of serratia protease in the pathogenesis of experimental Serratia marcescens pneumonia. Infect Immun (1983) 1.22

Infection and immunity mediated by the carbohydrate recognition domain of the Entamoeba histolytica Gal/GalNAc lectin. J Infect Dis (1999) 1.22

Isolation of auxotrophs of Bacteroides fragilis. Can J Microbiol (1978) 1.21

High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. Proc Natl Acad Sci U S A (1992) 1.20

Positive regulation of Clostridium difficile toxins. Infect Immun (1997) 1.17

Bacteriocin production by strains of Bacteroides isolated from human feces and the role of these strains in the bacterial ecology of the colon. Antimicrob Agents Chemother (1977) 1.16

Mutagenesis of the Clostridium difficile toxin B gene and effect on cytotoxic activity. Microb Pathog (1994) 1.14

TechLab and alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1. J Clin Microbiol (1999) 1.13

Transcriptional analysis of the toxigenic element of Clostridium difficile. Microb Pathog (1997) 1.13

Role of Clostridium difficile toxins in disease. Gastroenterology (1987) 1.11

The fecapentaenes, potent mutagens from human feces. Chem Res Toxicol (1992) 1.11

Carbohydrate repression of catalase synthesis in Bacteroides fragilis. J Bacteriol (1977) 1.11

Effect of high-fiber and high-oil diets on the fecal flora of swine. Appl Environ Microbiol (1987) 1.10

Production by Clostridium spiroforme of an iotalike toxin that possesses mono(ADP-ribosyl)transferase activity: identification of a novel class of ADP-ribosyltransferases. Infect Immun (1989) 1.09

Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. Infect Immun (1997) 1.07